研发创新
以自主创新为核心驱动力，
围绕代谢与慢病领域持续布局差异化研发管线
甘李药业始终活跃于国内外顶级学术舞台，通过会议摘要、口头报告、壁报等多种形式，与全球学者交流最新临床数据与研究进展。
科学会议
-
中华医学会糖尿病学分会第二十八次学术会议
28th Annual Scientific Meeting of the Chinese Diabetes Society · CDS 2026
即将开始 -
美国肥胖周
ObesityWeek · OW 2026
即将开始 -
欧洲糖尿病研究协会第62届年会
62nd Annual Meeting of the European Association for the Study of Diabetes · EASD 2026
查看会议资料 -
中华医学会第二十三次内分泌学学术会议
23rd Annual Scientific Meeting of the Chinese Society of Endocrinology CSE 2026
查看会议资料 -
美国糖尿病学会第86届科学年会
American Diabetes Association's 86th Scientific Sessions · ADA 2026
查看会议资料 -
中华医学会糖尿病学分会第二十七次学术会议
27th Annual Scientific Meeting of the Chinese Diabetes Society · CDS 2025
查看会议资料 -
美国肥胖周
ObesityWeek OW 2025
查看会议资料 -
欧洲糖尿病研究协会第61届年会
61st Annual Meeting of the European Association for the Study of Diabetes · EASD 2025
查看会议资料 -
美国糖尿病学会第85届科学年会
American Diabetes Association's 85th Scientific Sessions · ADA 2025
查看会议资料 -
中华医学会糖尿病学分会第二十六次学术会议
26th Annual Scientific Meeting of the Chinese Diabetes Society · CDS 2024
查看会议资料 -
美国肥胖周
ObesityWeek OW 2024
查看会议资料 -
欧洲糖尿病研究协会第60届年会
60th Annual Meeting of the European Association for the Study of Diabetes · EASD 2024
查看会议资料 -
美国糖尿病学会第84届科学年会
American Diabetes Association's 84th Scientific Sessions · ADA 2024
查看会议资料 -
欧洲糖尿病研究协会第59届年会
59th Annual Meeting of the European Association for the Study of Diabetes · EASD 2023
查看会议资料 -
2023国际糖尿病联虚拟盟虚拟大会
International Diabetes Federation Virtual Congress 2023 IDF Virtual Congress 2023
查看会议资料 -
欧洲糖尿病研究协会第57届年会
57th Annual Meeting of the European Association for the Study of Diabetes EASD 2021
查看会议资料
Pharmacokinetic and Pharmacodynamic Properties of Novel Once-Weekly Insulin GZR4 versus Insulin Degludec in Patients with Type 2 Diabetes
Insulin Ludefen(GZR4) · I期
Superior glycaemic control with once-weekly insulin GZR4 versus once-daily insulin glargine U100 in insulin-naïve type 2 diabetes: SUPER-1
Insulin Ludefen(GZR4) · III期
Superior glycaemic control with once-weekly insulin GZR4 versus once-daily insulin degludec in adults with basal insulin-treated type 2 diabetes: SUPER-2
Insulin Ludefen(GZR4) ·III期
Pharmacodynamic properties of novel once-daily insulin GZR33 in people with type 1 diabetes
GZR33 · I期
Pharmacokinetic and Pharmacodynamic Profiles of GZR102 Injection, a Novel Once-Weekly Fixed-Ratio Combination of Insulin GZR4 and GLP-1 Analog Bofanglutide
GZR102 ·临床前
Effect of Bofanglutide on the Pharmacokinetics of Metformin in Healthy Participants
Bofanglutide (GZR18) · I期
Effect of Renal Impairment on the Pharmacokinetics and safety of Bofanglutide.
Bofanglutide (GZR18) · I期
Effect of Renal Impairment on the Pharmacokinetics and safety of Bofanglutide.
博凡格鲁肽 (GZR18) · I期
Effect of Bofanglutide on the Pharmacokinetics of Metformin in Healthy Participants
博凡格鲁肽 (GZR18) · I期
Pharmacokinetic and Pharmacodynamic Profiles of GZR102 Injection, a Novel Once-Weekly Fixed-Ratio Combination of Insulin GZR4 and GLP-1 Analog Bofanglutide
GZR102 · 临床前
Effects of Moderate Renal Impairment on Pharmacokinetics and Safety of Once-weekly Insulin GZR4
Insulin Ludefen (GZR4) · I期
Safety, Tolerability, and Pharmacokinetic Characteristics of GZR102 Injection Compared with GZR4 or Bofanglutide
GZR102 · I期
Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
博凡格鲁肽 (GZR18) · IIb降糖
Superior Glycemic Control Achieved with Once-Weekly Insulin GZR4 Compared with Once-Daily Insulin Degludec in Insulin-Treated Chinese Subjects with T2D
Insulin Ludefen (GZR4) · II期-B部分
Comparable Glycemic Control of Once-Weekly Insulin GZR4 Relative to Once-Daily Insulin Degludec in Insulin-Naïve Chinese Subjects with T2D
Insulin Ludefen (GZR4) · II期-A部分
Bofanglutide (GZR18), a Novel GLP-1RA, Improved Glycemic Control and Cardiometabolic Risk Factors in Chinese Patients with T2D
博凡格鲁肽 (GZR18) · Ib/IIa降糖
Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D
博凡格鲁肽 (GZR18) · IIb降糖
Superior Glycemic Control Achieved with Once-Weekly Insulin GZR4 Compared with Once-Daily Insulin Degludec in Insulin-Treated Chinese Subjects with T2D
Insulin Ludefen (GZR4) · II期-B部分
Comparable Glycemic Control of Once-Weekly Insulin GZR4 Relative to Once-Daily Insulin Degludec in Insulin-Naïve Chinese Subjects with T2D
Insulin Ludefen (GZR4) · II期-A部分
Pharmacokinetic and pharmacodynamic properties of a novel once-weekly insulin analogue GZR4 in people with type 2 diabetes
Insulin Ludefen (GZR4) · Ib期
Safety, tolerability, and pharmacodynamic properties of a novel once-weekly insulin GZR4 in healthy subjects
Insulin Ludefen (GZR4) · Ia期
A Novel premix Insulin GZR101 for Diabetes Management
GZR101 · 临床前
Molecular and Pharmacological Properties of GZR4, a Once Weekly Insulin Analog
Insulin Ludefen (GZR4) · 临床前
A novel GLP-1 analog, GZR18, induced an 18.6% weight reduction in subjects with obesity in a phase Ib/IIa trial
博凡格鲁肽 (GZR18) · Ib/IIa期减重
Efficacy, safety, and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 1 diabetes
长秀霖 · III期1型糖尿病
Efficacy, safety, and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 2 diabetes
长秀霖 · III期2型糖尿病
会议动态与回顾
了解甘李药业在全球学术会议中的最新动态
-
2026-10-16
快速起效，无需起始负荷剂量！甘李药业胰岛素周制剂路达胰岛素与依柯胰岛素头对头Ⅲ期研究SUPER-8成功达到主要研究终点
2026年10月16日，甘李药业股份有限公司（以下简称“甘李药业”，股票代码：603087.SH）宣布，公司自主研发的超长效基础胰岛素周制剂路达胰岛素（Insulin Ludefen）注射液在中国开展的评价其与依柯胰岛素注射液（诺和期®）有效性和安全性的头对头关键Ⅲ期临床研究（SUPER-8）达到主要研究终点。
了解详情 -
2026-10-12
甘李药业重组人白蛋白制剂GLR1075注射液首个I期临床研究完成首例试验参与者给药
2026年10月12日——甘李药业股份有限公司（以下简称：甘李药业，股票代码：603087.SH）宣布，公司自主研发的重组人白蛋白GLR1075注射液，在健康试验参与者中单次和多次给药及在肝硬化腹水低白蛋白血症试验参与者中多次给药的中国I期临床研究，已于今日完成首例试验参与者给药。标志着GLR1075注射液的研发正式进入临床阶段，有望进一步拓展白蛋白类药物的供给来源，提升临床可及性。
了解详情 -
2026-09-18
甘李药业进军重组人白蛋白药物研究领域，GLR1075注射液获批临床试验
2026年9月18日，甘李药业股份有限公司（以下简称：甘李药业，股票代码：603087.SH）宣布，其自主研发的重组人白蛋白GLR1075注射液已正式获得国家药品监督管理局临床试验批准，拟用于治疗肝硬化腹水低白蛋白血症。
了解详情